A Phase I/II Study of CPI-613 in Combination With Induction/Consolidation in Older AML Patients

Trial Profile

A Phase I/II Study of CPI-613 in Combination With Induction/Consolidation in Older AML Patients

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs CPI 613 (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2016.
    • 26 Jul 2016 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped was Drug Supply Issues.
    • 22 Oct 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top